Results 161 to 170 of about 98,807 (272)

A Case of Unresectable Ampulla of Vater Carcinoma Successfully Treated with Conversion Surgery Following Sequential Systemic Chemotherapy Including Durvalumab. [PDF]

Surg Case Rep
Araki T, Muranushi R, Takagi K, Watanabe T, Okuno N, Fukasawa M, Kimura N, Tohmatsu Y, Shirai Y, Shibuya K, Yoshioka I, Hirabayashi K, Yasuda I, Fujii T.   +13 more
europepmc   +1 more source

Gastric Metastasis of Uterine Leiomyosarcoma Detected During Surveillance Endoscopy and Resected by Endoscopic Submucosal Dissection After Multiple Metachronous Metastases: A Case Report

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Uterine leiomyosarcoma (uLMS) is a rare, aggressive uterine malignancy that usually metastasizes hematogenously, whereas gastrointestinal involvement is uncommon. A 69‐year‐old woman with uLMS treated by hysterectomy and adjuvant chemotherapy developed metachronous lung, sigmoid colon, gallbladder, and abdominal wall metastases.
Yuiko Nagasawa, Takahiro Hiratsuka, Daisuke Minezaki, Wataru Miyoshino, Ryo Ogawa, Tomonori Akagi, Hidefumi Shiroshita, Yoshitake Ueda, Kazuhiro Mizukami, Masafumi Inomata   +9 more
wiley   +1 more source

Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guérin Versus Gemcitabine in Treatment-Naïve Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis. [PDF]

J Clin Med
Kim KH, Kang BJ, Lee CH, Kim S, Ku JY, Ha HK.   +5 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. [PDF]

Cancer Res
Pan CH, Lyu Y, Ghosh M, Siraj MA, Tseng R, Chaika NV, Haley JD, Khalvatifahlylani B, Tuveson DA, Patel HD, Faruque M, Rajacharya GH, Donnelly KL, Leiton CV, Mejia Arbelaez CM, Chen H, Chowdhury S, Sarkar S, Delgado Coka L, Roa-Peña L, Horowitz M, Marchenko N, Singh PK, Shroyer KR, Escobar-Hoyos LF.   +24 more
europepmc   +1 more source

Screening the Combination of Gemcitabine, Clomipramine, and Resveratrol in HL-60 Leukemia Cells. [PDF]

Curr Issues Mol Biol
Biltekin B, Elgormus Y, Bilir A.
europepmc   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin‐4 Expression: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Sarcomatoid urothelial carcinoma (UC) is an extremely rare and aggressive subtype with a poor prognosis. Reports on the efficacy of enfortumab vedotin (EV) in this subtype remain limited. Case Presentation A 74‐year‐old man presented with gross hematuria and was diagnosed with metastatic sarcomatoid UC of the urinary bladder with ...
Sonin Chon, Shoichi Nagamoto, Takahisa Yamashita, Kenta Fujii, Kazuki Yokota, Kojiro Tachibana, Sachi Kitayama, Yohei Okada, Satoru Kawakami, Akihiro Yano   +9 more
wiley   +1 more source

Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report. [PDF]

Clin Case Rep
Juan L, Weiping C.
europepmc   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source